Literature DB >> 35216722

Testosterone Replacement Therapy in Hypogonadal Men.

Christina Wang1, Ronald S Swerdloff2.   

Abstract

All approved testosterone replacement methods, when used according to recommendations, can restore normal serum testosterone concentrations, and relieve symptoms in most hypogonadal men. Selection of the method depends on the patient's preference with advice from the physician. Dose adjustment is possible with most delivery methods but may not be necessary in all hypogonadal men. The use of hepatotoxic androgens must be avoided. Testosterone treatment induces reversible suppression of spermatogenesis; if fertility is desired in the near future, human chronic gonadotropin, selective estrogen receptor modulator, estrogen antagonist, or an aromatase inhibitor that stimulates endogenous testosterone production may be used.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Endogenous testosterone stimulators; Implants; Intramuscular injections; Modified androgens; Oral capsules; Selective androgen receptor modulators; Transdermal gels

Mesh:

Substances:

Year:  2022        PMID: 35216722      PMCID: PMC8994707          DOI: 10.1016/j.ecl.2021.11.005

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  131 in total

1.  Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies.

Authors:  H M Behre; K Abshagen; M Oettel; D Hübler; E Nieschlag
Journal:  Eur J Endocrinol       Date:  1999-05       Impact factor: 6.664

2.  Global trends in testosterone prescribing, 2000-2011: expanding the spectrum of prescription drug misuse.

Authors:  David J Handelsman
Journal:  Med J Aust       Date:  2013-10-21       Impact factor: 7.738

3.  Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression.

Authors:  Andrea D Coviello; Alvin M Matsumoto; William J Bremner; Karen L Herbst; John K Amory; Bradley D Anawalt; Paul R Sutton; William W Wright; Terry R Brown; Xiaohua Yan; Barry R Zirkin; Jonathan P Jarow
Journal:  J Clin Endocrinol Metab       Date:  2005-02-15       Impact factor: 5.958

4.  Reexamination of pharmacokinetics of oral testosterone undecanoate in hypogonadal men with a new self-emulsifying formulation.

Authors:  Anthony Y Yin; Michelle Htun; Ronald S Swerdloff; Maruja Diaz-Arjonilla; Robert E Dudley; Sandra Faulkner; Rachelle Bross; Andrew Leung; Sima Baravarian; Laura Hull; James A Longstreth; Steven Kulback; Gregory Flippo; Christina Wang
Journal:  J Androl       Date:  2011-04-07

5.  Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis.

Authors:  Peter Y Liu; Ronald S Swerdloff; Peter D Christenson; David J Handelsman; Christina Wang
Journal:  Lancet       Date:  2006-04-29       Impact factor: 79.321

6.  Trough serum testosterone predicts the development of polycythemia in hypogonadal men treated for up to 21 years with subcutaneous testosterone pellets.

Authors:  Flora F Ip; Irene di Pierro; Ross Brown; Ilona Cunningham; David J Handelsman; Peter Y Liu
Journal:  Eur J Endocrinol       Date:  2009-11-10       Impact factor: 6.664

7.  AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function.

Authors:  C Steidle; S Schwartz; K Jacoby; T Sebree; T Smith; R Bachand
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

8.  A clinical trial of 7 alpha-methyl-19-nortestosterone implants for possible use as a long-acting contraceptive for men.

Authors:  Sigrid von Eckardstein; Gabriela Noe; Vivian Brache; Eberhard Nieschlag; Horacio Croxatto; Francisco Alvarez; Alfred Moo-Young; Irving Sivin; Narender Kumar; Margaret Small; Kalyan Sundaram
Journal:  J Clin Endocrinol Metab       Date:  2003-11       Impact factor: 5.958

9.  Treatment of primary hypogonadism in men by the transdermal administration of testosterone.

Authors:  J C Findlay; V Place; P J Snyder
Journal:  J Clin Endocrinol Metab       Date:  1989-02       Impact factor: 5.958

10.  Clomiphene increases free testosterone levels in men with both secondary hypogonadism and erectile dysfunction: who does and does not benefit?

Authors:  A T Guay; J Jacobson; J B Perez; M B Hodge; E Velasquez
Journal:  Int J Impot Res       Date:  2003-06       Impact factor: 2.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.